IDH1 and myelodysplastic syndrome: Olutasidenib is currently being investigated in a phase 1/2 open label, multicenter study in R/R or treatment naive IDH1-mutated AML or MDS patients, either as monotherapy or in combination with azacitidine (NCT02719574).